MTOR and ovarian carcinoma: Therefore the PI3K-AKT pathway may also participate in EMT which was mediated by down-regulation of RASAL2, raising the possibility that the PI3K-AKT pathway inhibitors or mTOR pathway inhibitors, such as rapamycin, may also be effective in the treatment of Ras pathway-activated ovarian cancer.